NeuroFrontiers

Host: Andrew Wilner, MD, FACP, FAAN Guest: Carri Polick, PhD, RN Two recent studies linked childhood stress and stressors experienced across the lifespan to the severity of multiple sclerosis (MS) symptoms. In fact, both childhood and adult stressors were associated with MS disability and the so-called invisible symptoms of pain interference and psychiatric morbidity while only adult stressors wer...

Host: Jennifer Caudle, DO Guest: Mitzi Joi Williams, MD The CHIMES trial is the first phase IV clinical trial focusing exclusively on Black and Hispanics living with multiple sclerosis (MS). Not only did this study reveal key details about the disease burden of MS in this patient population, but it also provides an example of how the cycle of health inequity in research efforts can be broken. Lear...

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Anibal Chertcoff, MD According to a recent study, psychiatric conditions like depression, anxiety, bipolar disorder, and schizophrenia may be early indicators of multiple sclerosis (MS) years before symptoms appear, which could enable the early diagnosis and treatment of patients with MS. Joining Dr. Charles Turck to share key details and findings fr...

Guest: Ahmed Abdelhak, MD The state of research to better detect multiple sclerosis activity is changing rapidly, with emerging assays and other tools seeking to predict the occurrence of MRI lesions or relapses in patients. To dive into the latest biomarker research for MS in children, tune in with Dr. Ahmed Abdelhak, Clinical Instructor of Neurology at the University of California San Francisco...

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Tirisham V. Gyang, MD Guest: Gopika Govindan Kutty, MD In past studies, it was seen that multiple sclerosis was more prevalent in White individuals from Northern European ancestry. However, more recent data is showing that MS can happen in anyone and everyone, and there may be slight clinical variations in the disease when we look at different demogr...

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jay Avasarala, MD, PhD The three disease-modifying therapies for MS added into the World Health Organization’s (WHO) Essential Medicines list is a great step forward for patients afflicted with this chronic disease and could also serve as a model for other neurological disorders. Dive in as Dr. Charles Turck talks to one member of the team who was re...

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Craig Chepke, MD, FAPA From a women's mental health pre-conference to new mechanisms of action coming into psychiatry for the first time in decades, there’s a lot to look forward to at this year’s meeting. Join Dr. Mary Katherine Cheeley as she gets more highlights from Dr. Craig Chepke, Medical Director of Excel Psychiatric Associates a...

Host: Andrew Wilner, MD, FACP, FAAN Guest: Eoin Flanagan, MB, BCh For the first time since 2008, the International Advisory Committee on Clinical Trials in Multiple Sclerosis have made updates to their diagnostic guidelines for patients with suspected multiple sclerosis (MS). Joining Dr. Andrew Wilner to discuss these key updates is Dr. Eoin Flanagan, the Chair of the Division of Multiple Sclerosi...

Host: Andrew Wilner, MD, FACP, FAAN Guest: John R. Corboy, MD Disease-modifying therapies (DMTs) reduce disease activity and slow the progression of disability in multiple sclerosis. But there were some challenges that came out of this recent study. To discuss the findings from this trial, Dr. Andrew Wilner is joined by Dr. John Corboy, Professor of Neurology and the Director of the Rocky Mountain...

Guest: Sergio Baranzini, PhD A recent study was designed by the International Multiple Sclerosis Genetics Consortium with the goal in mind to find out whether the severity of multiple sclerosis (MS) could be influenced by genetics. Dive in with Dr. Sergio Baranzini, Distinguished Professor of Neurology at the University of California San Fransico and Co-Senior Author of the study.

Host: Jerome Lisk, MD, MBA, M.S., FAAN Guest: Santosh Kumar, PhD In an effort to examine the correlation between HIV-induced aging and Alzheimer’s disease in the United States population, a team of researchers at the University of Tennessee Health Science Center are working to develop a novel drug delivery system. To learn more, Dr. Jerome Lisk is joined by Dr. Santosh Kumar to discuss his current...

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Ashley Baker, MSN, PMHNP Before COVID-19, HCPs and patients had a lot of access to virtual healthcare, but it wasn’t being fully utilized. So what should we know about the ongoing use of telemedicine and the Ryan Haight Act? Take a deep dive with Dr. Mary Katherine Cheeley as she speaks with Ashley Baker, Psychiatric Nurse Practitioner a...

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Avindra Nath, MD Researchers from the National Institutes of Health (NIH) found that 100 percent of the participants in this study had fatigue and experienced cognitive difficulties. So what can we learn from this new research to help us diagnose and treat patients with disabling neurological symptoms after they had COVID-19? To discuss the findings,...

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Lokesh Shahani, MD, PhD, MPH, FACP, FASAM Due to their clinical overlap, distinguishing between neurocognitive and psychiatric disorders can be challenging, but an accurate diagnosis is crucial for timely assessment and treatment. Find out how we can better identify and treat complex neurocognitive disorders such as Alzheimer's disease and other form...

Host: Jerome Lisk, MD, MBA, M.S., FAAN Guest: Rajesh Rajagopalan Tampi, MBBS, MS, DFAPA Behavioral and psychological symptoms of dementia (BPSD) refers to a group of noncognitive symptoms that commonly occur in patients with dementia. While data shows efficacy for treatment modalities for these symptoms and behaviors, the use of psychotropic medications has been met with controversy due to their a...

Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens" Guest: Dominique Higgins, MD, PhD Glioblastoma is the most common type of brain tumor while also being one of the most aggressive cancers in adults. So what do we need to know about ferroptosis? Dive in with Dr. Andrew Wilner as he’s joined by Dr. Dominique Higgins, Assistant Professor of Neuros...

Host: Jerome Lisk, MD, MBA, M.S., FAAN Guest: Rajesh Rajagopalan Tampi, MBBS, MS, DFAPA Find out what previous and ongoing clinical trials are telling us about the use of cannabinoids to treat behavioral and psychological symptoms of dementia (BPSD) with Dr. Jerome Lisk and Dr. Raj Tampi, Professor and Chairman of the Department of Psychiatry at Creighton School of Medicine.

Host: Jerome Lisk, MD, MBA, M.S., FAAN Guest: Rajesh Rajagopalan Tampi, MBBS, MS, DFAPA Here to share some of the key presentations at the 2023 American Psychiatric Association (APA) Annual Meeting is Dr. Raj Tampi, Professor and Chairman of the Department of Psychiatry at Creighton School of Medicine.

Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens" Guest: Selim R. Benbadis, MD It may be challenging for a family member to take a video on their cell phone while a patient is having a seizure. However, they have been deemed useful in helping physicians establish a history of seizures in epileptic patients. So should clinicians consider this as...

Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens" Guest: David Weisman, MD Alzheimer’s disease is the most common form of dementia, and symptoms become more severe over time. In fact, it’s the leading cause of disability and poor health in older adults. And although there’s no cure, a new medication called lecanemab recently received accelerate...

Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens" Guest: Marilyn J. Wooley PhD Due to the nature of their work, first responders may be at a higher risk for developing posttraumatic stress disorder (PTSD). So how can clinicians help their front-line patients with PTSD? Dr. Andrew Wilner will discuss this with Dr. Marilyn Wooley, Clinical Psycho...

Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens" Guest: Bruce Hermann, PhD Guest: Shlomo Shinnar, M.D., Ph. D. In hopes of learning more about how the brain changes due to aging in patients with childhood-onset epilepsy, a new study was funded that may suggest some interesting findings. So what do we need to know from the results of this study...

Host: Jerome Lisk, MD, MBA, M.S., FAAN Guest: Katherine Longardner, MD A recent five-year observational study aimed to determine the impact of individual autonomic domains that were associated with Parkinson’s disease. So what were the key findings of this study? Join Dr. Jerome Lisk as he welcomes Dr. Katherine Longardner, Assistant Professor of Neurosciences at UC San Diego Health, to discuss th...

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Deborah L. Korn, PsyD Eye movement desensitization and reprocessing (EMDR) therapy is an interactive psychotherapy used to relieve stress and reduce symptoms of trauma. It is most commonly associated with the treatment of posttraumatic stress disorder (PTSD). But can this therapy also treat other stress-related disorders? To go into further detail, D...

Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens" Guest: Sean Lawler, PhD The STING protein is a novel treatment pathway for cancer. How might it affect our patients’ immune response to diseases such as brain cancer? Dr. Sean Lawler, an Associate Professor in the Department of Pathology and Laboratory Medicine at Brown University in Providence,...